Ranok Therapeutics Expands Clinical Testing of CHAMP™ BRD4 Protein Degrader RNK05047 to China

Study follows ongoing Phase 1 trial in U.S. and will enroll patients in China to evaluate the first protein degrader developed using Ranok’s innovative CHAMP™ technology BOSTON, MA and HANGZHOU, China, March 11, 2024 -- Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers, today announced the initiation of patient dosing in China for a Phase 1 study of RNK05047, its first protein degrader candidate. The study, which mirrors an ongoing Phase 1 study in the U.S., will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RNK05047 in Chinese patients with advanced solid tumors or lymphomas. Ranok anticipates preliminary data from both the US and China Phase 1 studies by the end of 2024. “RNK05047, which has been developed using Ranok’s proprietary CHAMP™ technology, is the first BRD4-selective protein degrader to have entered clinical testing in China. This extends our ongoing clinical study of RNK05047 in the U.S. to an Asian patient population, which we believe will provide important insights,” said Weiwen Ying, Ph.D, Founder and Chief Executive Officer of Ranok. “RNK05047 degrades BRD4 protein preferentially in tumors, which may potentially lead to improved safety and efficacy. We look forward to sharing initial results from both the US and China studies later this year.” “BRD4 is an epigenetic target of great interest for the treatment of many different cancer types,” said Ning Li, M.D., Professor and Vice President of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) in Beijing China, as well as Lead Principal Investigator for this study. “The Cancer Hospital is the first and largest cancer hospital in China for the diagnosis and treatment of cancer. We are excited to be participating in this study and are hopeful that RNK05047 will provide an important new therapeutic option for cancer patients.” Additional information can be found at www.chinadrugtrials.org.cn (CTR20233943) and www.clinicaltrials.gov (NCT05487170). About Ranok’s CHAMP™ platform Ranok’s proprietary Chaperone-mediated Protein Degradation (CHAMP™) platform takes advantage of the cellular chaperone network, which regulates the folding and stability of proteins, distinguishing it from other targeted protein degradation approaches. CHAMPs have a number of unique advantages, such as the evasion of mechanisms of drug resistance, and are designed to improve safety and efficacy due to the selective targeting of disease tissues.

The release as fetched from its publisher. ranoktherapeutics.com ↗